Acute Myeloid Leukemia and molecularly defined subtypes
Research activity is centered on acute myeloid leukemia, including FLT3-mutated AML, NPM1-mutated AML, AML secondary to myeloproliferative neoplasms, and higher-risk myelodysplastic syndromes. The funded trials also address response assessment through minimal residual disease and remission depth in newly diagnosed and relapsed settings.
- FLT3-positive AML
- NPM1-mutated AML
- AML secondary to myeloproliferative neoplasms
- Higher-risk myelodysplastic syndromes
Clinical interest extends to treatment strategies for patients with limited sensitivity to intensive chemotherapy and to disease control in molecular relapse.
Acute Lymphoblastic Leukemia and Philadelphia chromosome-associated disease
The sponsor supports studies in adult acute lymphoblastic leukemia, with emphasis on Philadelphia chromosome-positive ALL, Philadelphia chromosome-negative ALL, Ph-like ALL, very high-risk T-lineage ALL, and B-cell ALL with persistent residual disease before transplantation. Several trials focus on deep remission and MRD negativity in high-risk disease.
- Ph+ ALL
- Ph-like ALL
- Very high-risk T-lineage ALL
- MRD-positive B-cell ALL
Therapeutic interests include approaches for relapsed or refractory disease and for patients with residual disease detected before haematopoietic stem cell transplantation.
Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
Another major area involves BCR-ABL1-positive chronic myeloid leukemia, especially in chronic phase and early chronic phase, with trials exploring treatment response, molecular remission, and disease control in newly diagnosed patients. In parallel, the sponsor funds studies in chronic lymphocytic leukemia, small lymphocytic lymphoma, and CLL-like monoclonal B-cell lymphocytosis, including patients with adverse biologic features.
- BCR-ABL1+ chronic myeloid leukemia
- Early chronic-phase CML
- Chronic lymphocytic leukemia
- CLL-like monoclonal B-cell lymphocytosis
These studies also include immune-mediated complications linked to CLL and treatment strategies aimed at improving depth of response in biologically high-risk disease.
Targeted therapy, immunotherapy, and disease control
The funded portfolio includes targeted and immune-based approaches across hematologic malignancies, with interest in tyrosine kinase inhibitors, BCL-2 inhibition, BTK inhibition, bispecific antibody therapy, and antibody-based treatment. These trials span both frontline and relapsed/refractory settings.
- Tyrosine kinase inhibitor-based treatment
- BCL-2 inhibitor combinations
- BTK inhibitor therapy
- Antibody-based and bispecific approaches
Specific areas include treatment of autoimmune hemolytic anemia associated with CLL, as well as disease control in multiple myeloma and persistent or recurrent disease.
Transplantation and high-risk hematologic disease
Several trials address the role of allogeneic transplantation and transplant-related decision-making in high-risk blood cancers, including patients with residual disease before transplant and those with high-risk myelodysplastic syndromes. Research also includes treatment strategies designed for patients unsuitable for intensive chemotherapy.
- Allogeneic stem cell transplantation
- Residual disease before transplantation
- High-risk myelodysplastic syndromes
- Transplant-oriented treatment planning
These studies are closely linked to efforts in molecular remission, relapse prevention, and management of patients with complex or resistant hematologic disease.
